Found: 27
Select item for more details and to access through your institution.
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
- Published in:
- Liver International, 2007, v. 27, n. 7, p. 938, doi. 10.1111/j.1478-3231.2007.01511.x
- By:
- Publication type:
- Article
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 199, n. 2, p. 371, doi. 10.1007/s10549-023-06912-4
- By:
- Publication type:
- Article
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 179, n. 2, p. 387, doi. 10.1007/s10549-019-05462-y
- By:
- Publication type:
- Article
Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2013, v. 20, p. 650, doi. 10.1245/s10434-013-3136-x
- By:
- Publication type:
- Article
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42744-y
- By:
- Publication type:
- Article
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42744-y
- By:
- Publication type:
- Article
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0066848
- By:
- Publication type:
- Article
Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2006, v. 98, n. 4, p. 273, doi. 10.1093/jnci/djj053
- By:
- Publication type:
- Article
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.
- Published in:
- 2003
- By:
- Publication type:
- journal article
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 156, n. 2, p. 301, doi. 10.1007/s10549-016-3750-y
- By:
- Publication type:
- Article
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 156, n. 2, p. 319, doi. 10.1007/s10549-016-3751-x
- By:
- Publication type:
- Article
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 139, n. 3, p. 789, doi. 10.1007/s10549-013-2587-x
- By:
- Publication type:
- Article
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
- Published in:
- International Journal of Colorectal Disease, 2017, v. 32, n. 8, p. 1179, doi. 10.1007/s00384-017-2800-1
- By:
- Publication type:
- Article
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 293, doi. 10.1007/s00280-012-1914-y
- By:
- Publication type:
- Article
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
- Published in:
- International Journal of Cancer, 2018, v. 143, n. 8, p. 2053, doi. 10.1002/ijc.31603
- By:
- Publication type:
- Article
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
- Published in:
- PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0147599
- By:
- Publication type:
- Article
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 375, doi. 10.1007/s11523-014-0342-9
- By:
- Publication type:
- Article
Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial.
- Published in:
- Oncologist, 2012, v. 17, n. 7, p. 900, doi. 10.1634/theoncologist.2011-0442
- By:
- Publication type:
- Article
MiR-210 Is Overexpressed in Tumor-infiltrating Plasma Cells in Triple-negative Breast Cancer.
- Published in:
- Journal of Histochemistry & Cytochemistry, 2020, v. 68, n. 1, p. 25, doi. 10.1369/0022155419892965
- By:
- Publication type:
- Article
The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer.
- Published in:
- Journal of Histochemistry & Cytochemistry, 2017, v. 65, n. 6, p. 335, doi. 10.1369/0022155417702849
- By:
- Publication type:
- Article
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial.
- Published in:
- Medical Oncology, 2012, v. 29, n. 3, p. 2291, doi. 10.1007/s12032-011-0103-x
- By:
- Publication type:
- Article
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 515, doi. 10.1007/s40259-019-00368-z
- By:
- Publication type:
- Article